Today: 30 June 2026
Browse Category

NSE:NATCOPHARM 1 December 2025 - 8 December 2025

Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook

Natco Pharma Share Price Today (8 December 2025): Q2 Results, Adcock Ingram Deal and 2026 Stock Outlook

Natco Pharma Limited is back in the spotlight as the stock trades lower on 8 December 2025 even while the company closes a landmark acquisition in South Africa and navigates life after its blockbuster Revlimid windfall. Around late morning on Monday, 8 December, Natco Pharma was trading near ₹908–₹910 on the NSE, down roughly 2.5–3% from Friday’s close of ₹933.60. The stock has moved in a wide intraday band of about ₹904–946 and remains roughly 40% below its 52‑week high of ₹1,505, despite a 6–8% gain over the past week.mint+2Moneycontrol+2
8 December 2025
·
Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Forecast

Natco Pharma Share Price Today (2 December 2025): Rating Reaffirmed, USFDA Update, South Africa Deal and 2026 Stock Forecast

Natco Pharma has had a busy few months: a big overseas acquisition in South Africa, a fresh USFDA inspection with Form 483 observations, strong-but-normalising earnings, and a credit-rating reaffirmation that reassured debt markets. The share price is finally stabilising after a brutal fall earlier in 2025, but the market is still arguing about what the stock is really worth. Below is a detailed, news-style rundown of where Natco Pharma Limited stands as of 2 December 2025, and how analysts and models are currently reading the stock.
2 December 2025
·
Natco Pharma Share Price Today (1 December 2025): Q2 Results, USFDA Update, Adcock Ingram Deal & 2026 Forecast

Natco Pharma Share Price Today (1 December 2025): Q2 Results, USFDA Update, Adcock Ingram Deal & 2026 Forecast

Mumbai, 1 December 2025 — Natco Pharma Limited is back in the spotlight. The stock is seeing heavy trading, fresh institutional interest and a sharp intraday bounce, even as investors digest softer Q2 FY26 earnings, a recent USFDA inspection in Chennai and a large acquisition in South Africa. As of around 11:05 am IST on 1 December 2025, Natco Pharma was quoted near ₹921 on the NSE, up almost 5% for the day. The stock has traded in a day range of ₹880–923, against a 52‑week band of ₹726.80–1,505, with volume close to 2.95 million shares, according to exchange data compiled by Moneycontrol. Moneycontrol
1 December 2025
··

Stock Market Today

  • Honeywell Shares Sink 6% After Aerospace Spin-Off Wraps Up
    June 30, 2026, 12:26 AM EDT. Honeywell Technologies (NYSE: HON) dropped over 6% Monday after its Honeywell Aerospace (NYSE: HONA) spin-off was completed. The aerospace business started trading solo as the new Honeywell Technologies shifts focus to building, process and industrial automation. Investors got one HONA share for every two HON, while Honeywell Technologies completed a 1-for-2 reverse split. CEO Vimal Kapur said the overhaul lets both companies focus growth and drive value. Honeywell Technologies now targets 2025 pro forma net sales of $19.9 billion, up 3%, and net income of $1.34 billion. The company reports next on July 23.
Go toTop